Download PDF

1. Company Snapshot

1.a. Company Description

Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally.It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use.The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis.


In addition, it distributes and sells third party medical equipment.The company was incorporated in 1984 and is headquartered in Oslo, Norway.

Show Full description

1.b. Last Insights on MEDI

Medistim ASA's recent performance was driven by robust revenue growth, with a 16.7% increase in Q2 2025, fueled by significant gains in the Americas and strategic product advancements. The company's strong fundamentals and growth potential have garnered attention in the European small-cap market, which has seen a positive uptick amid easing trade tensions and optimism surrounding potential U.S. interest rate cuts. A favorable market environment and expectations for lower U.S. borrowing costs have also contributed to investor optimism.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Exploring Three Undiscovered Gems In The European Market

Nov -24

Source:

Card image cap

Medistim ASA (FRA:MD1) Q3 2025 Earnings Call Highlights: Record Revenue Growth and Regional ...

Oct -26

Source:

Card image cap

Medistim (OB:MEDI) Margin Expansion Reinforces Strong Bullish Narratives Despite Valuation Concerns

Oct -25

Source:

Card image cap

Uncovering Europe's Undiscovered Gems This October 2025

Oct -07

Source:

Card image cap

Medistim ASA (FRA:MD1) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Aug -21

Source:

Card image cap

Undiscovered Gems In Europe Featuring Medistim And 2 Other Small Caps

Aug -20

Source:

Card image cap

Uncovering 3 Undiscovered European Gems with Promising Potential

Jul -09

Source:

Card image cap

Floridienne And 2 Other European Small Caps with Promising Potential

Jun -10

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (4.70%)

6. Segments

Own Products

Expected Growth: 5%

Strong demand for cardiovascular procedures, increasing adoption of minimally invasive surgeries, and Medistim's innovative products such as the TEE probe and ChillX system drive growth. Expanding distribution channels, strategic partnerships, and investments in R&D further support the 5% growth rate.

Third Party Products

Expected Growth: 3%

Strong demand for cardiovascular procedures, increasing adoption of minimally invasive surgeries, and strategic partnerships with hospitals and clinics drive growth for Medistim ASA's Third Party Products. Additionally, expanding product offerings and geographic presence contribute to the segment's growth.

7. Detailed Products

TEEprobe

A transesophageal echocardiography (TEE) probe designed for intraoperative and intensive care unit (ICU) use

QPULSA

A non-invasive, ultrasound-based cardiac output monitor

LlowFlow

A low-flow perfusion system for cardiopulmonary bypass surgery

QPULSA Verifi

A non-invasive, ultrasound-based cardiac output monitor with advanced analytics

8. Medistim ASA's Porter Forces

Forces Ranking

Threat Of Substitutes

Medistim ASA operates in the medical technology industry, where substitutes are limited. However, the company's products may face competition from alternative treatments or procedures.

Bargaining Power Of Customers

Medistim ASA's customers are primarily hospitals and healthcare providers, who have limited bargaining power due to the specialized nature of the company's products.

Bargaining Power Of Suppliers

Medistim ASA relies on a few key suppliers for components and materials, which gives them some bargaining power. However, the company's strong relationships with suppliers mitigate this risk.

Threat Of New Entrants

The medical technology industry has high barriers to entry, including regulatory hurdles and significant R&D investments. This limits the threat of new entrants.

Intensity Of Rivalry

The medical technology industry is highly competitive, with several established players competing for market share. Medistim ASA faces intense rivalry from companies such as Abbott and Medtronic.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 4.25%
Debt Cost 3.95%
Equity Weight 95.75%
Equity Cost 7.73%
WACC 7.57%
Leverage 4.43%

11. Quality Control: Medistim ASA passed 9 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Medistim

A-Score: 5.0/10

Value: 0.7

Growth: 6.2

Quality: 9.2

Yield: 3.8

Momentum: 8.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Revenio

A-Score: 4.1/10

Value: 1.1

Growth: 7.3

Quality: 8.4

Yield: 1.9

Momentum: 1.5

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Ion Beam Applications

A-Score: 3.7/10

Value: 6.3

Growth: 4.1

Quality: 4.1

Yield: 2.5

Momentum: 1.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
CellaVision

A-Score: 3.5/10

Value: 1.3

Growth: 6.7

Quality: 8.0

Yield: 1.9

Momentum: 0.5

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Xvivo Perfusion

A-Score: 3.3/10

Value: 0.8

Growth: 9.8

Quality: 7.5

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
ReWalk Robotics

A-Score: 3.0/10

Value: 9.8

Growth: 4.0

Quality: 4.1

Yield: 0.0

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

248.0$

Current Price

248$

Potential

-0.00%

Expected Cash-Flows